Literature DB >> 33737301

Disparities in Hepatocellular Carcinoma Incidence, Stage, and Survival: A Large Population-Based Study.

Yvonne N Flores1,2,3, Geetanjali D Datta2,4,5, Liu Yang6, Edgar Corona6, Divya Devineni6, Beth A Glenn7,2, Roshan Bastani7,2, Folasade P May2,6,8.   

Abstract

BACKGROUND: Liver cancer is one of the most rapidly increasing cancers in the United States, and hepatocellular carcinoma (HCC) is its most common form. Disease burden and risk factors differ by sex and race/ethnicity, but a comprehensive analysis of disparities by socioeconomic status (SES) is lacking. We examined the relative impact of race/ethnicity, sex, and SES on HCC incidence, stage, and survival.
METHODS: We used Surveillance, Epidemiology, and End Results (SEER) 18 data to identify histologically confirmed cases of HCC diagnosed between January 1, 2000 and December 31, 2015. We calculated age-adjusted HCC incidence, stage at diagnosis (local, regional, distant, unstaged), and 5-year survival, by race/ethnicity, SES and sex, using SEER*Stat version 8.3.5.
RESULTS: We identified 45,789 cases of HCC. Incidence was highest among low-SES Asian/Pacific Islanders (API; 12.1) and lowest in high-SES Whites (3.2). Incidence was significantly higher among those with low-SES compared with high-SES for each racial/ethnic group (P < 0.001), except American Indian/Alaska Natives (AI/AN). High-SES API had the highest percentage of HCC diagnosed at the local stage. Of all race/ethnicities, Blacks had the highest proportion of distant stage disease in the low- and high-SES groups. Survival was greater in all high-SES racial/ethnic groups compared with low-SES (P < 0.001), except among AI/ANs. Black, low-SES males had the lowest 5-year survival.
CONCLUSIONS: With few exceptions, HCC incidence, distant stage at diagnosis, and poor survival were highest among the low-SES groups for all race/ethnicities in this national sample. IMPACT: HCC prevention and control efforts should target low SES populations, in addition to specific racial/ethnic groups. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 33737301      PMCID: PMC8172467          DOI: 10.1158/1055-9965.EPI-20-1088

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  24 in total

1.  Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008.

Authors:  Sean F Altekruse; Katherine A McGlynn; Lois A Dickie; David E Kleiner
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

2.  Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data.

Authors:  Mandi Yu; Zaria Tatalovich; James T Gibson; Kathleen A Cronin
Journal:  Cancer Causes Control       Date:  2013-11-01       Impact factor: 2.506

Review 3.  Toward an Intersectional Approach in Developmental Science: The Role of Race, Gender, Sexual Orientation, and Immigrant Status.

Authors:  Negin Ghavami; Dalal Katsiaficas; Leoandra Onnie Rogers
Journal:  Adv Child Dev Behav       Date:  2016-02-15

4.  Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States.

Authors:  H S Kim; L Rotundo; J D Yang; D Kim; N Kothari; M Feurdean; C Ruhl; A Unalp-Arida
Journal:  J Viral Hepat       Date:  2017-07-03       Impact factor: 3.728

5.  Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999-2009.

Authors:  Stephanie C Melkonian; Melissa A Jim; Brigg Reilley; Jennifer Erdrich; Zahava Berkowitz; Charles L Wiggins; Donald Haverkamp; Mary C White
Journal:  Cancer Causes Control       Date:  2018-07-20       Impact factor: 2.506

6.  Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004.

Authors:  Yvonne N Flores; Hal F Yee; Mei Leng; José J Escarce; Roshan Bastani; Jorge Salmerón; Leo S Morales
Journal:  Am J Gastroenterol       Date:  2008-07-30       Impact factor: 10.864

Review 7.  The epidemiology of obesity.

Authors:  Cynthia L Ogden; Susan Z Yanovski; Margaret D Carroll; Katherine M Flegal
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

Review 8.  Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis.

Authors:  Yezaz Ahmed Ghouri; Idrees Mian; Julie H Rowe
Journal:  J Carcinog       Date:  2017-05-29

9.  Socioeconomic and Racial/Ethnic Disparities in Cancer Mortality, Incidence, and Survival in the United States, 1950-2014: Over Six Decades of Changing Patterns and Widening Inequalities.

Authors:  Gopal K Singh; Ahmedin Jemal
Journal:  J Environ Public Health       Date:  2017-03-20

10.  An expert consensus for the management of chronic hepatitis B in Asian Americans.

Authors:  M J Tong; C Q Pan; S-H B Han; D S-K Lu; S Raman; K-Q Hu; J K Lim; H W Hann; A D Min
Journal:  Aliment Pharmacol Ther       Date:  2018-02-26       Impact factor: 8.171

View more
  4 in total

1.  Disparities in Risk of Advanced-Stage Liver Cancer and Mortality by Race and Ethnicity.

Authors:  Delfino Y Li; Trang VoPham; Mei-Tzu C Tang; Christopher I Li
Journal:  J Natl Cancer Inst       Date:  2022-09-09       Impact factor: 11.816

2.  Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma.

Authors:  Taotao Zhang; Yunlong Cui; Yanjin Wu; Jiahui Meng; Linmeng Han; Jiaqi Zhang; Chunyu Zhang; Chenxi Yang; Lu Chen; Xue Bai; Kai Zhang; Kaiyuan Wu; Michael N Sack; Lingdi Wang; Lu Zhu
Journal:  Clin Transl Med       Date:  2022-05

Review 3.  Epidemiologic and socioeconomic factors impacting hepatitis B virus and related hepatocellular carcinoma.

Authors:  Bipul Gnyawali; Antoinette Pusateri; Ashley Nickerson; Sajid Jalil; Khalid Mumtaz
Journal:  World J Gastroenterol       Date:  2022-08-07       Impact factor: 5.374

4.  Targeting population groups with heavier burden of hepatocellular carcinoma incidence: A nationwide descriptive epidemiological study in Sweden.

Authors:  Juan Vaz; Patrik Midlöv; Malin Sternby Eilard; Berne Eriksson; David Buchebner; Ulf Strömberg
Journal:  Int J Cancer       Date:  2022-03-12       Impact factor: 7.316

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.